Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

55.20USD
17 Nov 2017
Change (% chg)

$0.03 (+0.05%)
Prev Close
$55.17
Open
$55.00
Day's High
$55.43
Day's Low
$54.76
Volume
3,377,173
Avg. Vol
2,954,693
52-wk High
$66.80
52-wk Low
$54.41

Select another date:

Thu, Nov 16 2017

BRIEF-Cue Biopharma announces collaboration with Merck

* ‍Cue Biopharma says a strategic research collaboration and license agreement with Merck

BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6

* Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​ Source text: [http://bit.ly/2z57b4q] Further company coverage:

BRIEF-Merck reports final results of any and all tender offers

* Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​

BRIEF-Merck announces pricing of any and all tender offers

* Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​

FDA OKs Merck drug that prevents infection post-stem cell transplant

Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

FDA OKs Merck drug to stop infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients

* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients

BRIEF-Merck & Co updates on investigation of co's Italian unit

* Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing

Top Massachusetts court weighs Merck case over generic drug injury

Massachusetts' top court on Monday weighed whether the makers of brand name drugs like Merck & Co Inc can be sued over injuries blamed not on their own products but generic versions of the drugs other companies made.

Select another date: